When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AMRX - Amneal in-licenses myasthenia gravis candidate from Kashiv Bio
Amneal Pharmaceuticals Inc. Class A
Amneal Pharmaceuticals (AMRX-18.6%) inks an agreement with privately held Kashiv BioSciences for exclusive U.S. rights to Phase 2-stage K127 (pyridostigmine) for the treatment of myasthenia gravis, a rare autoimmune disorder characterized by weakness in the skeletal muscles.
More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,